What Is Desmopressin Used For? Approved Uses, Per the Label

Desmopressin is a prescription medicine, a synthetic analogue of the natural hormone vasopressin (antidiuretic hormone). In the United States it has been approved in several dosage forms, including oral tablets, sublingual tablets, nasal sprays and solutions for injection, under names including DDAVP, Noctiva and Nocdurna. The approved indications fall into two families: conditions involving excess urine output or excess night time urine production, and selected bleeding conditions in which desmopressin raises circulating factor VIII activity and von Willebrand factor. This page describes those indications as they are framed in US prescribing information, outlines the kinds of studies behind them, and summarises what published literature reports. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or any medicine.

Approved indications at a glance

US label versions on DailyMed: DDAVP (desmopressin acetate) tablets, DailyMed label version February 2021; DDAVP (desmopressin acetate) injection, DailyMed label version September 2022. The current label for the specific product governs.

Central diabetes insipidus

The oldest and most central approved use of desmopressin is antidiuretic replacement in central diabetes insipidus, a condition in which the pituitary does not release enough vasopressin and the kidneys cannot concentrate urine. The label frames the indication as replacement therapy for the antidiuretic deficiency rather than as a treatment for nephrogenic forms of the disease, where the kidney does not respond to the hormone. The related label statement covers temporary polyuria and polydipsia following head trauma or surgery in the pituitary region, a situation that is often transient.

Much of the modern evidence base in this area concerns how exposure and response vary across patients rather than whether the antidiuretic effect exists. A 2025 pediatric study used real world data together with pharmacokinetic and pharmacodynamic model simulations to characterise desmopressin exposure and antidiuretic response in children, and the researchers reported substantial variability between individuals in that population (PMID 39462098). Formulation research has also continued in parallel, including a 2023 translational study that described a bioinspired buccal stretching patch intended to boost the systemic absorption of peptide drugs (PMID 37756378); delivery systems of that kind are research stage rather than approved products.

Primary nocturnal enuresis

US prescribing information for oral desmopressin tablets includes management of primary nocturnal enuresis, the persistent bedwetting that occurs in children who have never had sustained dry nights. The rationale on the label follows the antidiuretic mechanism: reducing overnight urine volume so that bladder capacity is less likely to be exceeded during sleep.

Relapse after stopping treatment has been a recurring theme in the published literature. A 2016 meta analysis published in Pediatrics examined desmopressin withdrawal strategies in children treated for enuresis, and the researchers reported that structured, gradual withdrawal was associated with lower relapse rates than abrupt discontinuation (PMID 27343233). The same pediatric pharmacokinetic and pharmacodynamic modelling work noted above described how real world dosing data in children were used to simulate response, which speaks to the wide between child variability that clinicians weigh in this indication (PMID 39462098).

Regulatory history matters here. US regulators later removed the primary nocturnal enuresis indication from intranasal desmopressin formulations after reports of severe hyponatremia and seizures, leaving oral tablets as the approved presentation for this indication. That change is one of the clearest examples of a desmopressin indication being narrowed on safety grounds rather than efficacy grounds.

Nocturia due to nocturnal polyuria in adults

A separate and more recent family of approvals covers nocturia in adults, defined on those labels as awakening at least two times per night to void, where the underlying problem is nocturnal polyuria rather than bladder storage failure or another cause. Two product specific presentations were developed for this indication in the United States: a low dose nasal spray and a sublingual tablet. Both carry a boxed warning in their US labeling about hyponatremia, and both labels describe sodium monitoring expectations and populations in which the medicine is contraindicated.

The clinical framing behind this indication is captured in the review literature. A 2018 review in Reviews in Urology discussed how nocturia has been defined and classified, and the authors described nocturnal polyuria as a distinct mechanism separate from reduced bladder capacity (PMID 30787675). A 2019 review of management strategies for nocturia in Current Urology Reports summarised behavioural and pharmacologic approaches and placed desmopressin within the options studied for nocturnal polyuria, while noting hyponatremia risk as a central safety consideration (PMID 31707521). The sex specific dosing distinctions that appear on the nocturia labels came out of the development programmes for those products, reflecting observed differences in hyponatremia risk.

Hemophilia A and type 1 von Willebrand disease

Desmopressin also holds a hematologic indication that has nothing to do with urine output. Injectable desmopressin, and historically a high concentration nasal spray, are labeled for patients with hemophilia A or type 1 von Willebrand disease who have factor VIII activity above a threshold stated on the label, for control of bleeding episodes or to cover surgical and dental procedures. The mechanism involves release of stored von Willebrand factor and a rise in factor VIII activity rather than any effect on coagulation factor synthesis.

A 2003 review in Seminars in Thrombosis and Hemostasis examined desmopressin in mild hemophilia A and addressed indications, limitations, efficacy and safety, and the authors described the need for a test dose to confirm an adequate individual response as well as limitations such as diminishing response with repeated administration (PMID 12640572). That review is a useful illustration of why the label restricts the indication by disease type and by baseline factor VIII activity: patients with severe hemophilia A do not have releasable stores to mobilise.

Regulatory history of the indications

The sequence of approvals explains why the desmopressin label landscape looks fragmented today.

1. Antidiuretic indications first. Central diabetes insipidus and post pituitary surgery polyuria were the founding indications, carried across injection, intranasal and later oral presentations.
2. Enuresis added, then narrowed. Primary nocturnal enuresis was added for oral and intranasal forms, and the intranasal enuresis indication was later withdrawn in the United States following hyponatremia reports.
3. Nocturia approved as its own indication. Rather than extending an existing label, regulators approved separate low dose products specifically for nocturia due to nocturnal polyuria in adults, each with a boxed hyponatremia warning and defined monitoring language.
4. Hematologic indication maintained separately. The hemophilia A and type 1 von Willebrand disease indication sits on the injectable product and the high concentration nasal presentation, with eligibility limited by baseline factor VIII activity.

Because desmopressin products differ by route, concentration and indication, the approved use attached to one product does not transfer to another. Which product carries which indication is a question for a prescribing clinician and the current prescribing information for that specific product.

Uses that are not approved indications

One short factual note for completeness: several other uses of desmopressin appear in the literature and are not approved indications. These include bleeding prophylaxis before percutaneous kidney biopsy, examined in a 2021 safety analysis (PMID 34590925) and in a 2025 narrative review of the role of desmopressin in kidney biopsies (PMID 41333971); use as part of strategies to control the rate of sodium correction in hyponatremia, discussed in reviews of hyponatremia treatment (PMID 20539224); and perioperative administration in oncology surgery, studied in a phase II dose escalation trial in breast cancer patients (PMID 26306290). These are investigational or off label contexts, not label indications.

Hyponatremia and Other Adverse Events: What Studies Report

Low serum sodium dominates the published safety discussion for desmopressin, which follows directly from the mechanism of water retention. A 2019 review of nocturia management described hyponatremia as the principal safety concern limiting desmopressin use in older adults with nocturnal polyuria (PMID 31707521). Reviews of hyponatremia management more broadly have emphasised that both the degree and the speed of sodium change matter: a 2010 review of hyponatremia treatment summarised the risks associated with rapid correction and with undertreatment (PMID 20539224), and a 2022 review of hypertonic saline use reported on meeting correction goals while avoiding harm (PMID 34508830).

In the hematologic setting, the 2003 review of mild hemophilia A discussed safety alongside efficacy and limitations, including the constraints that follow repeated administration (PMID 12640572). In nephrology, a 2021 study of desmopressin given as bleeding prophylaxis around kidney biopsy reported on the safety of that practice (PMID 34590925), and a 2025 narrative review assessed the accumulated evidence in the same setting (PMID 41333971); both describe an off label context rather than a label indication. A 2015 phase II dose escalation trial of perioperative desmopressin in breast cancer patients reported on tolerability in that investigational setting (PMID 26306290).

Questions a prescribing clinician answers

• Whether a given symptom pattern reflects an approved indication, such as central diabetes insipidus or nocturnal polyuria, or another cause.
• Which approved product and route, if any, matches the indication under discussion.
• What baseline and follow up sodium testing, fluid considerations and contraindications apply in a specific case.
• How other medicines and conditions interact with desmopressin.

None of those questions can be settled from a summary page. Anyone considering desmopressin, or already using it, discusses the question with a licensed prescribing clinician.

References

• Desmopressin dosing in children using real-world data and pharmacokinetic/pharmacodynamic model simulations (Pediatric Research, 2025)
• Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis (Pediatrics, 2016)
• Nocturia: Finding an Identity (Reviews in Urology, 2018)
• Management Strategies for Nocturia (Current Urology Reports, 2019)
• Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety (Seminars in Thrombosis and Hemostasis, 2003)
• Hypertonic Saline for Hyponatremia: Meeting Goals and Avoiding Harm (American Journal of Kidney Diseases, 2022)
• Treatment of hyponatremia (Current Opinion in Nephrology and Hypertension, 2010)
• Safety of renal biopsy bleeding prophylaxis with desmopressin (Journal of International Medical Research, 2021)
• The Role of Desmopressin in Kidney Biopsies: A Narrative Review (Canadian Journal of Kidney Health and Disease, 2025)
• A phase II dose-escalation trial of perioperative desmopressin in breast cancer patients (SpringerPlus, 2015)
• Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch (Science Translational Medicine, 2023)